RNA Sequencing-Guided Treatment Selection Shows Promise in Metastatic Renal Cell Carcinoma
核心洞察
The OPTIC RCC phase II trial demonstrated that RNA sequencing-based molecular subtyping can effectively guide treatment selection in metastatic clear cell renal cell carcinoma (搜索) patients.
Patients with angiogenic cluster 1/2 tumors treated with cabozantinib plus nivolumab achieved a 76% objective response rate with 100% of patients showing tumor burden reduction.
The biomarker-driven approach represents a significant advancement toward personalized treatment strategies in kidney cancer (搜索), with operational improvements reducing cluster assignment time from 40 to 20 days.
The prospective phase II OPTIC RCC trial has demonstrated that RNA sequencing-based molecular subtyping can effectively guide treatment selection in patients with metastatic clear cell renal cell carcinoma (搜索) (ccRCC (搜索)), achieving remarkable clinical outcomes in a biomarker-selected population.
Trial Design and Patient Selection
The OPTIC RCC trial (NCT05361720) represents a novel biomarker-driven approach to treating metastatic ccRCC (搜索). Patients are assigned to specific treatment regimens based on RNAseq-defined molecular clusters: those with angiogenic-driven tumors (cluster 1/2) receive nivolumab plus cabozantinib, while patients with immune-inflamed tumors (cluster 4/5) are treated with ipilimumab plus nivolumab.
The study enrolled patients with an ECOG performance score of 0 or 1, metastatic ccRCC (搜索) without prior systemic therapy, and available tissue for RNA sequencing. Of the 27 patients analyzed in the cluster 1/2 cohort, the median age was 68 years, with 56% male, 89% White, and 70% having an ECOG performance status of 0. Notably, 41% of patients were in the favorable-risk IMDC prognostic group.
Clinical Outcomes
The trial met its primary endpoint with an objective response rate of 76% among patients with cluster 1/2 tumors treated with cabozantinib plus nivolumab. The responses included 2 patients with complete response (8%), 17 with partial responses (68%), 6 with stable disease (24%), and no patients with progressive disease.
"Of the 6 patients with stable disease, 3 just missed the criteria for objective response, but are very close at 27%, 27%, and 29%," noted Scott M. Haake, MD, PhD, assistant professor of medicine at Vanderbilt School of Medicine (搜索)'s Division of Hematology & Oncology.
Remarkably, 100% of tumors demonstrated tumor burden reduction, with a median reduction of 42% (range, 5%-100%). At a median follow-up of 11.1 months (range, 0.9-31.5), 17 of 27 patients remained on the study.
Molecular Insights
The investigators compared gene expression patterns between tumors with the most versus least tumor shrinkage, revealing distinct molecular signatures. Preliminary results showed that several metabolic pathways were enriched in tumors with the most tumor shrinkage, while increased epithelial transition expression correlated with decreased tumor shrinkage.
"Selection of patients exhibiting an angiogenic gene expression signature enriches for clinical outcomes to cabozantinib plus nivolumab, including high objective response rate, reduction of tumor burden for all patients, and lack of progressive disease," Haake explained during the presentation at the 2025 ESMO Congress.
Operational Improvements
The study demonstrated significant operational improvements throughout its conduct. The investigators optimized their turnaround time for sequencing and data analysis, reducing the consent-to-cluster assignment period from 40 days to 20 days. According to Haake, "The rate-limiting step was typically acquisition of tissue, especially when biopsies or surgical samples were obtained at outside facilities that needed to be shipped to Vanderbilt before submission."
Scientific Foundation
The OPTIC RCC trial builds upon findings from the randomized phase III IMmotion 151 trial, which evaluated atezolizumab plus bevacizumab versus sunitinib in treatment-naive kidney cancer (搜索) patients. Using machine learning models applied to IMmotion 151 data, researchers identified seven distinct tumor clusters, with cluster 1/2 exhibiting strong angiogenic gene expression signatures and favorable progression-free survival outcomes with anti-angiogenic therapies.
"The goal was to take these tumor clusters or gene expression signatures that retrospectively correlated with drug response and prospectively evaluate their ability to enrich for drug response," Haake explained. The trial successfully demonstrated that this biomarker-driven approach could be implemented within an interventional clinical trial framework.
Broader Implications
The success of the OPTIC RCC trial represents a significant step toward personalized medicine in kidney cancer (搜索) treatment. By using molecular subtyping to match patients with optimal therapies, the approach could potentially improve outcomes while avoiding unnecessary toxicities from less effective treatments.
The cluster 4/5 portion of the study remains open for accrual, with findings from this immune-inflamed tumor cohort treated with ipilimumab plus nivolumab expected to provide additional insights into biomarker-guided treatment selection in metastatic ccRCC (搜索).